Isorhapontigenin alleviates pulmonary fibrosis by inhibiting oxidative stress-induced senescence via STAT3/PRDX2 signals in alveolar epithelial cells
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115287 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Suwan Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, …. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Alveolar Epithelial Cells, Peroxiredoxins, Idiopathic Pulmonary Fibrosis. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease, is predominantly driven by oxidative stress-induced alveolar epithelial cell (AEC) senescence. However, effective therapeutic strategies for IPF remain rudimentary. Here, we demonstrate that isorhapontigenin (ISO), a compound known to mitigate oxidative damage and mitochondrial lipid peroxidation, attenuates pulmonary fibrosis by targeting peroxiredoxin 2 (PRDX2). Utilizing bleomycin-induced murine models and TGF-β-treated BEAS-2B cells, we demonstrated that ISO markedly attenuate histopathological alterations and extracellular matrix deposition associated with pulmonary fibrosis, while concurrently mitigating alveolar epithelial cell senescence. Integrative analyses combining network pharmacology and proteomics identified PRDX2 as a principal molecular target of ISO. Further molecular docking studies and drug affinity responsive target stability (DARTS) assays revealed that ISO engages PRDX2 through STAT3, establishing a key molecular bridge for their interaction. Notably, LC-MS/MS-based proteomics combined with single-cell sequencing further revealed a pronounced downregulation of PRDX2 expression in fibrotic lung tissues. Knockdown of PRDX2 exacerbated fibrotic progression, underscoring its protective role in pulmonary homeostasis. Mechanistically, ISO alleviates oxidative stress and prevents AEC senescence through PRDX2 upregulation, thereby offering a novel therapeutic strategy for IPF. These findings not only establish PRDX2 as a pivotal regulator of pulmonary fibrosis but also highlight ISO as a promising therapeutic candidate for IPF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Pulmonary and Critical Care Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
- Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China; Department of Pulmonary and Critical Care Medicine, Th…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, S., Yuan, A., Fan, S., Ding, X., Zhang, S., Li, Y., & Dai, J. (2025). Isorhapontigenin alleviates pulmonary fibrosis by inhibiting oxidative stress-induced senescence via STAT3/PRDX2 signals in alveolar epithelial cells. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115287
Vancouver
Chen S, Yuan A, Fan S, Ding X, Zhang S, Li Y, et al. Isorhapontigenin alleviates pulmonary fibrosis by inhibiting oxidative stress-induced senescence via STAT3/PRDX2 signals in alveolar epithelial cells. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115287
BibTeX
@article{Chen2025,
author = {Chen, Suwan and Yuan, An and Fan, Shiwen and Ding, Xiaorui and Zhang, Shenao and Li, Yuting and Dai, Jinghong},
title = {Isorhapontigenin alleviates pulmonary fibrosis by inhibiting oxidative stress-induced senescence via STAT3/PRDX2 signals in alveolar epithelial cells},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115287}
}
EUVIMED